… plus erlotinib in Korean patients with HLRCC-associated RCC. … patients who received
bevacizumab plus erlotinib as second or more line of treatment, the median time from the first-line …

… First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive
non-small-cell lung cancer: analyses from the Phase III, randomized, open-label, …

… Prespecified subgroup analyses were planned to evaluate efficacy of erlotinib 100 mg/d in
treatment-naïve patients, patients with different EGFR mutations (exon 19 deletions, L858R …

… subset was in line with that observed in previous trials of the anti-VEGF monoclonal antibody
bevacizumab plus erlotinib vs erlotinib alone conducted in Japanese patients; specifically, …

… Patients with advanced non-squamous NSCLC harbouring EGFR-mutation were randomly
(… combination with erlotinib (150 mg daily) plus bevacizumab (15 mg/kg iv q3w) or erlotinib (…

… ) patients with brain metastases. We assessed whether concurrent erlotinib with WBRT is safe
and benefits patients … In summary, 9 patients (8.5%) in the WBRT with concurrent erlotinib …

… on patients who received second-line treatment. … for second-line treatment of patients
with mPAC that has progressed following gemcitabine-based therapy and is the first second-line …

… TKIs (gefitinib / erlotinib). Osimertinib is now a treatment option for patients with advanced
NSCLC … may ever receive the clinical benefit of osimertinib if treated in the second line (Fig. 2). …

… used, including gefitinib/erlotinib in 38 patients and icotinib in 15 patients. The third-… used
in 22 patients, but mostly as the treatment following first-line TKIs (Fig. S2). Five patients were …

… In South Korea, for example, gefitinib appeared to be prescribed preferentially to afatinib
and erlotinib in older patients. There was no evidence, however, that afatinib was less effective …